Matthew Ros

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Cambridge, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Evan D. Kearns, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Matthew Ros

Form 4 holding Chief Operating Officer

Verastem, Inc.

Security class
Common Stock
Shares / value
50,000
Estimated value
$352,000
Report date
01 Apr 2025
Price
$7.04
Ownership
Direct
Form 4 holding Executive Vice President, Chief Strategy & Business Officer

Epizyme, Inc.

Security class
Common Stock, par value $0.0001
Shares / value
111,313
Estimated value
$156,951
Report date
16 Aug 2021
Price
$1.41
Ownership
Direct
Form 4 holding Executive Vice President, Chief Strategy & Business Officer

Epizyme, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
134,178
Estimated value
Report date
16 Aug 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Matthew Ros

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .